Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global $6.7 Bn Ovarian Cancer Opportunity Analysis and Forecasts to 2028 - ResearchAndMarkets.com

November 5, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 5, 2019--

The “Ovarian Cancer: Opportunity Analysis and Forecasts to 2028” report has been added to ResearchAndMarkets.com’s offering.

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028 values the Ovarian Cancer market at $1.8bn in 2018 across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) and expects it to grow to $6.7bn in the following ten years with a compound annual growth rate (CAGR) of 14.4%.

The main drivers of growth will be the adoption of maintenance therapy across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan), poly ADP-ribose polymerase (PARP) inhibitor uptake in the first-line setting, the launch of new pipeline agents, and increased screening rates for genetic markers.

Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type.

The dramatic growth in the ovarian cancer market is largely attributed to the label expansions for PARP inhibitors such as Lynparza, Zejula and Rubraca. The increase in screening rates for genetic markers such as BRCA mutations and other homologous recombination deficiencies (HRDs) will enable better patient segmentation and are expected to further drive the use of PARP inhibitors.

In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market. Moreover, by 2028, another major revenue contributor will be new drug classes - notably, immune checkpoint inhibitors, with five expected to enter the market bringing combined forecasted revenues of around $1.4bn.

A major barrier for growth in the ovarian cancer market, however, will be the emerging use of biosimilars and generics for some key marketed products, namely Lynparza and angiogenesis inhibitor Avastin. Despite advancements in the treatment of newly-diagnosed ovarian cancer patients, one of the largest unmet needs, the need for effective treatment options for the relapsed platinum-resistant patients, will remain unaddressed.

In addition, the unmet need for early-stage diagnostic biomarkers and specialized treatment options for rare histological subtypes of ovarian cancer will also remain, which will provide further opportunities for diagnostics companies and drug developers.


Reasons to Buy

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Double-Digit Growth Rate Expected for Ovarian Cancer Between 2018-2028

2.2 Drug Developers Expand Labels Through Novel Combinations and Broadening of Patient Eligibility

2.3 Unmet Need for More Effective Therapies in the Treatment-Resistant Disease Setting Will Largely Remain Unaddressed

2.4 An Individualized Treatment Paradigm Emerges for the First-Line Setting, While Targeted Therapies Are Struggling to Deliver for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors

5.3 Global and Historical Trends

5.3.1 7MM Trends in Diagnosed Incidence

5.3.2 7MM Trends in Observed Survival

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Ovarian Cancer (2018-2028)

5.5.1 Diagnosed Incident Cases of Ovarian Cancer

5.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer

5.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer

5.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype

5.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation

5.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation

5.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD

5.5.9 Diagnosed Incident Cases of EOC with FR Overexpression

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Front-Line Therapies

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients

7.4 Individualized Treatment Approaches

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer

7.6 An Early-Stage Diagnostic for Ovarian Cancer

8 R&D Strategies

8.1 Overview

8.1.1 PARP Inhibitors Are Becoming a Focus of Clinical Development

8.1.2 Development of Companion Diagnostic and Robust Biomarker Platforms

8.1.3 Novel Mechanism of Action: Folate Receptor Alpha Targeting

8.1.4 Cell-Based Therapies at the Early Stages of Clinical Development

8.1.5 Platinum-Refractory Disease: Patients Might Have to Wait for Breakthrough Therapies

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Endpoints

8.2.2 Future Clinical Trial Endpoints

8.2.3 Moving Beyond the Current Platinum-Sensitive/Resistant Paradigm for Patient Recruitment in Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research - KOLs Interviewed for This Report

11.5 Primary Research - Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Directors

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/86ck30

View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005512/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/05/2019 04:36 AM/DISC: 11/05/2019 04:36 AM